Background: In April 2017, the Australian Government announced the full subsidy of continuous glucose monitors (CGM) to children and young people <21 years with type 1 diabetes (T1D). This study aimed to evaluate the effect of CGM on psychosocial outcomes in a T1D pediatric population-based sample. Methods: Children with T1D, commencing CGM between June 2017 and January 2018, and their parents were recruited in a prospective cohort study in a tertiary pediatric hospital in Western Australia. Parents and children older than 12 years self-completed questionnaires at onset of CGM and 2 months later, on fear of hypoglycemia (FOH) and diabetes treatment satisfaction (DTS). Parents provided measures of sleep quality. Children completed the Gold hypoglycemia awareness score. Hemoglobin A1c (HbA1c) values were compared at baseline (BL) and follow-up (FU). Results: Sixty parents and 38 children provided measures at BL and FU. Parental total FOH decreased (mean score BL vs. FU; 50.0 vs. 44.3, P = 0.004) with reduction in the Worry subscore (28.2 vs. 24.2, P = 0.004). Furthermore, parental and child DTS increased. Parental sleep quality improved (P < 0.001) and overnight finger prick testing decreased (P < 0.001). Impaired hypoglycemic awareness decreased in children (26.3% vs. 10.5%, P = 0.031). HbA1c reduced from 8.4% (68 mmol/mol) to 8.1% (65 mmol/mol) (P = 0.036). Conclusions: Introduction of subsidized CGM showed early improvement in psychosocial and glycemic outcomes in patients and their families in Western Australia. Ongoing evaluation is essential to assess whether equitable access to CGM will translate to sustained benefits for Australian T1D pediatric patients.
Background: In April 2017, the Australian Government announced the full subsidy of continuous glucose monitors (CGM) to children and young people <21 years with type 1 diabetes (T1D). This study aimed to evaluate the effect of CGM on psychosocial outcomes in a T1D pediatric population-based sample. Methods:Children with T1D, commencing CGM between June 2017 and January 2018, and their parents were recruited in a prospective cohort study in a tertiary pediatric hospital in Western Australia. Parents and children older than 12 years self-completed questionnaires at onset of CGM and 2 months later, on fear of hypoglycemia (FOH) and diabetes treatment satisfaction (DTS). Parents provided measures of sleep quality. Children completed the Gold hypoglycemia awareness score. Hemoglobin A1c (HbA1c) values were compared at baseline (BL) and follow-up (FU). Results: Sixty parents and 38 children provided measures at BL and FU. Parental total FOH decreased (mean score BL vs. FU; 50.0 vs. 44.3, P = 0.004) with reduction in the Worry subscore (28.2 vs. 24.2, P = 0.004). Furthermore, parental and childDTS increased. Parental sleep quality improved (P < 0.001) and overnight finger prick testing decreased (P < 0.001). Impaired hypoglycemic awareness decreased in children (26.3% vs. 10.5%, P = 0.031). HbA1c reduced from 8.4% (68 mmol/mol) to 8.1% (65 mmol/mol) (P = 0.036). Conclusions: Introduction of subsidized CGM showed early improvement in psychosocial and glycemic outcomes in patients and their families in Western Australia. Ongoing evaluation is essential to assess whether equitable access to CGM will translate to sustained benefits for Australian T1D pediatric patients.
Entities:
Keywords:
Continuous glucose monitoring; Government subsidy; Psychosocial outcomes; Type 1 diabetes
Authors: Molly L Tanenbaum; Dessi P Zaharieva; Ananta Addala; Priya Prahalad; Julie A Hooper; Brianna Leverenz; Ana L Cortes; Nora Arrizon-Ruiz; Erica Pang; Franziska Bishop; David M Maahs Journal: Diabet Med Date: 2022-08-08 Impact factor: 4.213
Authors: Karishma A Datye; Daniel R Tilden; Angelee M Parmar; Eveline R Goethals; Sarah S Jaser Journal: Curr Diab Rep Date: 2021-05-15 Impact factor: 4.810
Authors: Stephanie R Johnson; Deborah J Holmes-Walker; Melissa Chee; Arul Earnest; Timothy W Jones; Maria Craig; Kym Anderson; Geoff Ambler; Helen Barrett; Jenny Batch; Philip Bergman; Fergus Cameron; Peter Colman; Louise Conwell; Chris Cooper; Jennifer Couper; Elizabeth Davis; Martin de Bock; Kim Donaghue; Jan Fairchild; Gerry Fegan; Spiros Fourlanos; Sarah Glastras; Leonie Gray; Shane Hamblin; Paul Hofman; Dianne Jane Holmes-Walker; Neville Howard; Michelle Jack; Steven James; Craig Jefferies; Stephanie Johnson; Jeff Kao; Bruce R King; Antony Lafferty; Michelle Martin; Robert McCrossin; Mark Pascoe; Ryan Paul; Dorota Pawlak; Alexia Peña; Sarah Price; Darrell Price; Christine Rodda; David Simmons; Richard Sinnott; Alan Sive; Carmel Smart; Monique Stone; Steve Stranks; Elaine Tham; Charles Verge; Glenn Ward; Ben Wheeler; Judy Williams; Helen Woodhead; Nick Woolfield; Anthony Zimmermann Journal: Diabetes Care Date: 2022-02-01 Impact factor: 19.112